Innovotech Inc (IOT) - Total Liabilities
Based on the latest financial reports, Innovotech Inc (IOT) has total liabilities worth CA$784.68K CAD (≈ $567.62K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Innovotech Inc cash conversion from operations to assess how effectively this company generates cash.
Innovotech Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how Innovotech Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Innovotech Inc's assets to evaluate the company's liquid asset resilience ratio.
Innovotech Inc Competitors by Total Liabilities
The table below lists competitors of Innovotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trio Petroleum Corp.
NYSE MKT:TPET
|
USA | $1.91 Million |
|
Nexgel Inc
NASDAQ:NXGL
|
USA | $5.57 Million |
|
Noroo Holdings Co Ltd
KO:000325
|
Korea | ₩463.91 Billion |
|
Soco Corporation Ltd
AU:SOC
|
Australia | AU$6.35 Million |
|
KST Beteiligungs AG
F:KSW
|
Germany | €3.01 Million |
|
Enlitic Inc
AU:ENL
|
Australia | AU$4.24 Million |
|
Nutritional Growth Solutions Ltd
AU:NGS
|
Australia | AU$1.55 Million |
|
Archidply Decor Limited
NSE:ADL
|
India | Rs245.74 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Innovotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Innovotech Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Innovotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Innovotech Inc (2003–2025)
The table below shows the annual total liabilities of Innovotech Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$784.68K ≈ $567.62K |
+31.48% |
| 2024-12-31 | CA$596.80K ≈ $431.72K |
+173.85% |
| 2023-12-31 | CA$217.93K ≈ $157.65K |
+31.84% |
| 2022-12-31 | CA$165.29K ≈ $119.57K |
-35.44% |
| 2021-12-31 | CA$256.04K ≈ $185.22K |
+44.28% |
| 2020-12-31 | CA$177.46K ≈ $128.37K |
+0.38% |
| 2019-12-31 | CA$176.79K ≈ $127.89K |
-1.15% |
| 2018-12-31 | CA$178.86K ≈ $129.38K |
-48.27% |
| 2017-12-31 | CA$345.76K ≈ $250.12K |
-77.60% |
| 2016-12-31 | CA$1.54 Million ≈ $1.12 Million |
+26.95% |
| 2015-12-31 | CA$1.22 Million ≈ $879.64K |
+3.53% |
| 2014-12-31 | CA$1.17 Million ≈ $849.63K |
+18.33% |
| 2013-12-31 | CA$992.54K ≈ $717.99K |
+56454.93% |
| 2003-12-31 | CA$1.75K ≈ $1.27K |
-95.64% |
| 2003-09-30 | CA$40.22K ≈ $29.10K |
-- |
About Innovotech Inc
Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assa… Read more